Mylan pays $30M to settle charges of misleading investors on EpiPen rebates

Mylan pays $30M to settle charges of misleading investors on EpiPen rebates

More reads

• White House weighs limits on U.S. portfolio flows into China. (Bloomberg)
• Mylan pays $30 million to settle charges of misleading investors over probe into EpiPen Medicaid rebates. (STAT)
• Gene-test fraud billed $2.1 billion to U.S. Medicare program. (Bloomberg)